All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
Results from the phase II study (NCT01897571) of tazemetostat, a selective oral EZH2 inhibitor, in patients with relapsed/refractory (R/R) follicular lymphoma (FL) show encouraging clinical efficacy and safety.
This study evaluated the safety and efficacy of tazemetostat in patients with R/R FL with mutant or wild-type EZH2 FL. Tazemetostat was tolerable, with a low prevalence of treatment-related adverse events, and demonstrated good clinical efficacy even in high-risk subgroups. Results from this trial have been recently reported in Lancet Oncology.
Key safety and efficacy results were presented at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition; read more here. Based on the phase II trial results, tazemetostat has been granted supplemental new drug application approval by the U.S. Food and Drug Administration (FDA) for the treatment of R/R FL with EZH2 mutation and R/R FL with no alternative treatment options.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox